✦ LIBER ✦

1422 POSTER Observational Cohort Study of Plasma Levels of Biomarkers in Patients With Non-small Cell Lung Cancer Treated With Bevacizumab

✍ Scribed by L. Iqlesias; A. Rodriguez-Garzotto; M.T. Agullo-Ortufio; S. Ponce; V. Diaz-Garcia; A. Agudo-Lopez; C. Perez; J.A. Nufiez-Sobrino; J.A. Lopez-Martin; H. Cortes-Funes

Book ID: 117661408
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 44 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(11)70915-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9073 POSTER Clinical Outcomes for Bevaci

9073 POSTER Clinical Outcomes for Bevacizumab (BV)-treated Elderly Patients With Non-small Cell Lung Cancer (NSCLC) – Results From the ARIES Observational Cohort Study (OCS)

✍ Wozniak, A.; Kosty, M.R.; Jahanzeb, M.; Garst, J.; Spigel, D.; Leon, L.; Fish, S 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Posttreatment plasma VEGF levels may be

Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy

✍ She-Juan An, Yi-Sheng Huang, Zhi-Hong Chen, Jian Su, Yan Yang, Jian-Guang Chen, 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 268 KB

9086 POSTER Effectiveness of Bevacizumab

9086 POSTER Effectiveness of Bevacizumab (BV) Maintenance in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Treated in US Community Practices

✍ Thomas, S.; Ravelo, A.; Yu, E.; Dranitsaris, G.; Kalberer, T.; Beegle, N. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Reaction of plasma hepatocyte growth fac

Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs

✍ Hidenori Tanaka; Tatsuo Kimura; Shinzoh Kudoh; Shigeki Mitsuoka; Tetsuya Watanab 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 242 KB

## Abstract Hepatocyte growth factor induces resistance to epidermal growth factor receptor tyrosine kinase inhibitors. It has been hypothesized that epidermal growth factor receptor tyrosine kinase inhibitors administration may influence the levels of plasma hepatocyte growth factor. Patients with

9006 Safety of bevacizumab (BV) combined

9006 Safety of bevacizumab (BV) combined with chemotherapy (CTX) in patients (pts) with non-small cell lung cancer (NSCLC): interim results from the ARIES Lung observational cohort study (OCS)

✍ Jahanzeb, M.; Fischbach, N.; Kosty, M.; Kumar, P.; Spigel, D.; Wozniak, A.; Teng 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

9020 POSTER DISCUSSION Use of Bevacizuma

9020 POSTER DISCUSSION Use of Bevacizumab (BV) After Induction Therapy is Associated With Survival Benefit in Patients (pts) With Non-small Cell Lung Cancer (NSCLC) in the ARIES Observational Cohort Study (OCS)

✍ Kostv, M.P.; Brahmer, J.R.; Jahanzeb, M.; Kumar, P.; Robles, R.; Wozniak, A.J.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB